https://scholars.lib.ntu.edu.tw/handle/123456789/580450
標題: | Concurrent chemoradiotherapy for locally advanced esophageal cancer - A pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil | 作者: | CHIH-HUNG HSU KUN-HUEI YEH Lui L.T. Lee Y.-C. Bu C.-F. HSIU-PO WANG Lin J.-T. ANN-LII CHENG |
公開日期: | 1999 | 卷: | 19 | 期: | 5 C | 起(迄)頁: | 4463-4467 | 來源出版物: | Anticancer Research | 摘要: | Background: Concurrent chemoradiotherapy (CCRT) has recently become a promising treatment for esophageal cancer. However, most investigators have adopted the conventional or modified Wayne-State PF (cisplatin plus 5-fluorouracil) regimen, which is inevitably associated with moderate to severe treatment-related toxicities. In this pilot study, we incorporated a daily low-dose regimen of cisplatin and 5-fluorouracil into CCRT in order to improve the compliance of the patients. Patients and Methods: Between July 1993 and Dec. 1997, 25 patients with locally advanced esophageal cancer (T3, or N1 disease), received CCRT which consisted of daily low-dose cisplatin (6 mg/m2/day) and continuous infusion of 5-FU (225 mg/m2/day) with radiotherapy (fraction size = 200-250 cGy/day). Except for the initial 9 patients, for whom post-CCRT esophagectomy was compulsory, all subsequent patients underwent esophagectomy only when inadequate response to CCRT was noted. The scheduled radiation dose was 50 Gy for the first 9 patients, and 60 Gy for the rest of the patients. Results: Eighteen patients (72%) completed the CCRT without interruption. Clinically, there were 8 CR and 9 PR, with a total response rate of 68% (47-87%, 95% C.I.). All patients were evaluable for toxicity. Grade 3/4 leukopenia and thrombocytopenia developed in 14 (56%) and 7 (28%) patients, respectively. Grade 3/4 non-hematologic toxicity was seen in 4 (16%) patients. The median survival of the whole group was 8 months (range: 2-59+). The projected 3-year overall survival was 24%. Conclusion: We suggest that for locally advanced esophageal cancer CCRT with the aforementioned daily low-dose regimen, is a treatment with good patient compliance. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033427153&partnerID=40&md5=703f07f557c304b201b75db4f44afd30 https://scholars.lib.ntu.edu.tw/handle/123456789/580450 |
ISSN: | 0250-7005 | SDG/關鍵字: | antineoplastic metal complex; cisplatin; fluorouracil; pyrimidine antagonist; adult; advanced cancer; aged; article; cancer survival; clinical article; continuous infusion; esophagus cancer; female; human; leukopenia; male; multimodality cancer therapy; priority journal; radiation dose; thrombocytopenia; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Pilot Projects; Radiation-Sensitizing Agents; Survival Rate |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。